A pilot, open-label, balanced, randomized, fourperiod, two-sequence, two-treatment cross-over study to study the relative bioavailability of test Ivabradine prolonged release tablets (15 mg) given once a day versus CoralanA film-coated tablets (7.5 mg) twice a day at 12 hours apart under fasting and fed conditions in healthy human male subjects
Latest Information Update: 12 Nov 2019
At a glance
- Drugs Ivabradine (Primary)
- Indications Angina pectoris
- Focus Pharmacokinetics
- Sponsors Abbott Healthcare
- 15 Dec 2017 New trial record